Late-stage trial shows MS drug effectiveness, Novartis says

12/14/2008 | Wall Street Journal, The

Novartis AG reported preliminary data from a late-stage trial showing that 0.5 mg and 1.25 mg doses of FTY720, a drug candidate for multiple sclerosis, were more effective in reducing relapse than Avonex, an injectable drug from Biogen Idec. Novartis said it may seek FDA approval for FTY720 at the end of next year.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA